Generic Varubi Availability
Last updated on Apr 10, 2025.
Varubi is a brand name of rolapitant, approved by the FDA in the following formulation(s):
VARUBI (rolapitant hydrochloride - emulsion;intravenous)
-
Manufacturer: TERSERA
Approval date: October 25, 2017
Strength(s): EQ 166.5MG BASE/92.5ML (EQ 1.8MG BASE/ML) (discontinued) [RLD]
VARUBI (rolapitant hydrochloride - tablet;oral)
-
Manufacturer: TERSERA
Approval date: September 1, 2015
Strength(s): EQ 90MG BASE [RLD]
Is there a generic version of Varubi available?
No. There is currently no therapeutically equivalent version of Varubi available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Varubi. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
NK.sub.1 antagonists
Patent 7,049,320
Issued: May 23, 2006
Inventor(s): Paliwal; Sunil et al.
Assignee(s): Schering Corporation (Kenilworth, NJ)A NK.sub.1 antagonist having the formula (I), ##STR00001## wherein Ar.sup.1 and Ar.sup.2 are optionally substituted phenyl or heteroaryl, X.sup.1 is an ether, thio or imino linkage, R.sup.4 and R.sup.5 are not both H or alkyl, and the remaining variables are as defined in the specification, useful for treating a number of disorders, including emesis, depression, anxiety and cough. Pharmaceutical compositions. Methods of treatment and combinations with other agents are also disclosed.
Patent expiration dates:
- August 19, 2028✓✓✓
- August 19, 2028
-
Pharmaceutical formulations: salts of 8-[{1-(3,5-Bis-(trifluoromethyl)phenyl)-ethoxy}-methyl]-8-phenyl-1,7-diaz- a-spiro[4.5]decan-2-one and treatment methods using the same
Patent 7,563,801
Issued: July 21, 2009
Inventor(s): Qiu; Zhihui et al.
Assignee(s): Schering Corporation (Kenilworth, NJ)Pharmaceutical formulations containing salts of (5S,8S)-8-[{(1R)-1-(3,5-Bis-(trifluoromethyl)phenyl]-ethoxy}-methyl]-8-ph- enyl-1,7-diazaspiro [4.5]decan-2-one, represented by Formula I, are disclosed. Disclosed also are methods of treatment utilizing such dosage forms.
Patent expiration dates:
- April 4, 2027✓
- April 4, 2027
-
Pharmaceutical formulations: salts of 8-[{1-(3,5-bis-(trifluoromethyl)phenyl)-Ethoxy}-methyl]-8-phenyl-1,7-diaz- a-spiro[4.5]decan-2-one and treatment methods using the same
Patent 7,981,905
Issued: July 19, 2011
Inventor(s): Qiu; Zhihui et al.
Assignee(s): OPKO Health, Inc. (Miami, FL)Pharmaceutical formulations containing salts of (5S,8S)-8-[{(1R)-1-(3,5-Bis-(trifluoromethyl)phenyl]-ethoxy}-methyl]-8-ph- enyl-1,7-diazaspiro[4.5]decan-2-one, represented by Formula I, are disclosed. Disclosed also are methods of treatment utilizing such dosage forms.
Patent expiration dates:
- April 4, 2027✓
- April 4, 2027
-
Hydrochloride salts of 8-[{1-(3,5-Bis-(trifluoromethyl)phenyl)-ethoxy)-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one and preparation process therefor
Patent 8,178,550
Issued: May 15, 2012
Inventor(s): Hu Mengwei & Paliwal Sunil & Shih Neng-Yang & Guenter Frank Bruno & Mergelsberg Ingrid
Assignee(s): OPKO Health, Inc.Disclosed are hydrochloride and tosylate crystalline salt forms of (5S,8S)-8-[{(1R)-1-(3,5-Bis-(trifluoromethyl)phenyl)-ethoxy}-methyl]-8-phenyl-1,7-diazaspiro[4.5]decan-2-one, represented by Formula I and methods of preparing the same.
Patent expiration dates:
- April 4, 2027✓✓
- April 4, 2027
-
Tablet formulations containing 8-[{1-(3,5-Bis-(trifluoromethyl)phenyl)-ethoxy}-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one salts and tablets made therefrom
Patent 8,361,500
Issued: January 29, 2013
Inventor(s): Qiu Zhihui & Cho Wing-Kee Philip & Zhao Na & Wong Victor Ming-she
Assignee(s): Opko Health, Inc.Pharmaceutical formulations containing a salt of (5S,8S)-8-[{(1R)-1-(3,5-Bis-(trifluoromethyl)phenyl)-ethoxy}-methyl]-8-phenyl-1,7-diazaspiro[4.5]decan-2-one, represented by Formula I, which are suitable for forming into a tablet dosage form, as well as tablet dosage forms are disclosed. Disclosed also are methods of treatment utilizing such dosage forms.
Patent expiration dates:
- October 9, 2029✓
- October 9, 2029
-
Pharmaceutical formulations:salts of 8-[1-3,5-bis-(trifluoromethyl)phenyl)-ethoxymethyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one and treatment methods using the same
Patent 8,404,702
Issued: March 26, 2013
Inventor(s): Qiu Zhihui & Reyderman Larisa
Assignee(s): Opko Health, Inc.Pharmaceutical formulations containing salts of (5S,8S)-8-[{(1R)-1-(3,5-Bis-(trifluoromethyl)phenyl]-ethoxy}-methyl]-8-phenyl-1,7-diazaspiro[4.5]decan-2-one, represented by Formula I, are disclosed. Disclosed also are methods of treatment utilizing such dosage forms.
Patent expiration dates:
- April 4, 2027✓
- April 4, 2027
-
Hydrochloride salts of 8-[{1-(3,5-Bis-trifluoromethyl)phenyl)-ethoxy}-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one and preparation process therefor
Patent 8,470,842
Issued: June 25, 2013
Inventor(s): Hu Mengwei & Paliwal Sunil & Shih Neng-Yang & Guenter Frank Bruno & Mergelsberg Ingrid
Assignee(s): OPKO Health, Inc.Disclosed are hydrochloride and tosylate crystalline salt forms of (5S,8S)-8-[{(1R)-1-(3,5-Bis-(trifluoromethyl)phenyl)-ethoxy}-methyl]-8-phenyl-1,7-diazaspiro[4.5]decan-2-one, represented by Formula I and methods of preparing the same.
Patent expiration dates:
- January 18, 2029✓
- January 18, 2029
-
Intravenous formulations of neurokinin-1 antagonists
Patent 9,101,615
Issued: August 11, 2015
Inventor(s): Wan Jiansheng & Gupta Pranav & Monteith David & Bhattacharya Soumendu
Assignee(s): OPKO Health, Inc.Pharmaceutical compositions for intravenous administration comprising the compound of Formula I
Patent expiration dates:
- July 14, 2032✓
- July 14, 2032
More about Varubi (rolapitant)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (1)
- Drug images
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: NK1 receptor antagonists
- Breastfeeding
- En español
Patient resources
- Varubi drug information
- Varubi (Rolapitant Intravenous) (Advanced Reading)
- Varubi (Rolapitant Oral) (Advanced Reading)
Professional resources
Related treatment guides
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
